BioVie's Bezisterim Full Dataset From Phase 2a Trial In Parkinson's Disease, Patients Experienced Significant Improvements In Both Non-Motor Symptoms And Motor Control While Placebo-Treated Patients Worsened
Portfolio Pulse from Benzinga Newsdesk
BioVie announced that its Phase 2a trial for bezisterim in Parkinson's Disease showed significant improvements in both non-motor and motor symptoms for treated patients, while placebo-treated patients worsened.
May 22, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioVie's Phase 2a trial for bezisterim in Parkinson's Disease showed significant improvements in both non-motor and motor symptoms for treated patients, while placebo-treated patients worsened.
The positive results from the Phase 2a trial are likely to boost investor confidence in BioVie's product pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100